Cambrex Corp. (CBM) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Cambrex Reports Third Quarter 2018 Financial Results
November 8, 2018 6:40 AM EST- Acquired Halo Pharma, broadening capabilities, enhancing revenue growth and expanding customer base -
- Conference call at 8:30 a.m. ET on November 8, 2018 -
EAST RUTHERFORD, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, reports results for the third quarter ended September 30, 2018.
Third Quarter 2018 Highlights
Completed the acquisition of Halo Pharma (Halo), a leading finished dosage form Contract Development and... More